GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Incyte Corporation (INCY) [hlAlert]

Rating:
Buy INCY
up 1,286.72 %

Incyte Corporation (INCY) rated Buy with price target $135 by UBS

Posted on: Wednesday,  Nov 4, 2015  1:25 PM ET by UBS

UBS rated Buy Incyte Corporation (NASDAQ: INCY) on 11/04/2015. Previously UBS rated Buy Incyte Corporation (NASDAQ: INCY) on 11/02/2007., when
the stock price was $8.21. Since then, Incyte Corporation has gained 1286.72% as of 01/14/2016's recent price of $113.85.
If you would have followed the previous UBS's recommendation on INCY, you would have gained 1286.72% of your investment in 2995 days.

Incyte Corporation (Incyte) is a drug discovery and development company focused on developing small molecule drugs to treat serious unmet medical needs. The Company has a pipeline with programs in oncology, inflammation and diabetes. Incyte?s pipeline includes compounds in various stages of development in the areas of oncology, inflammation, diabetes and human immunodeficiency virus (HIV).

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/4/2015 1:25 PM Buy
None
117.29 135.00
as of 8/27/2015
1 Week up  11.61 %
1 Month up  4.15 %
3 Months up  6.62 %
1 YTD up  124.86 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/13/2014 11:25 AM Buy
None
65.75 90.00
9/6/2013 12:25 PM Buy
None
35.41 42.00
8/2/2013 2:25 PM Buy
None
26.91 28.00
4/27/2012 11:25 AM Buy
None
21.99 26.00
4/8/2011 11:25 AM Buy
None
17.00 20.00
2/15/2008 9:25 AM Buy
None
12.20 15.00
1/15/2008 9:25 AM Buy
None
11.16 14.00
11/2/2007 9:25 AM Buy
None
8.21 11.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy